Olema Pharmaceuticals, Inc. (OLMA): Depreciation & Amortization
$490.0K
Year ended 2025-12-31
$451.0K
Trailing 12 months to 2026-06-30
+11.1%
3-year compound annual growth
+113.7%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $490.0K | +24.7% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $393.0K | +4.2% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $377.0K | +5.6% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $357.0K | +119.0% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $163.0K | n/m | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $11.0K | +22.2% | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | $9.0K | n/a | 2022-02-28, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $490.0K | +24.7% |
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $2.42M | +8.4% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $1.02M | +21.2% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $3.06M | +48.3% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $9.26M | -26.0% |
| Geron Corp (GERN) | 2025-12-31 | $474.0K | -13.2% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $500.0K | -28.6% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $1.74M | +154.6% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $1.60M | +14.3% |
Compare OLMA, RIGL, RAPP, ARDX side by side · Screen every company in Pharmaceutical Preparations ↗